Placebos

"Placebos" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol.

Descriptor ID	D010919
MeSH Number(s)	D26.660 E02.785
Concept/Terms	Placebos Placebos Sham Treatment

Below are MeSH descriptors whose meaning is more general than "Placebos".

Chemicals and Drugs [D]
Pharmaceutical Preparations [D26]
Placebos [D26.660]
Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Therapeutics [E02]
Placebos [E02.785]

Below are MeSH descriptors whose meaning is related to "Placebos".

Below are MeSH descriptors whose meaning is more specific than "Placebos".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Placebos" by people in this website by year, and whether "Placebos" was a major or minor topic of these publications.

Bar chart showing 121 publications over 30 distinct years, with a maximum of 12 publications in 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1993	0	3	3
1994	0	4	4
1995	0	1	1
1996	0	3	3
1997	0	8	8
1998	0	2	2
1999	0	5	5
2000	0	2	2
2001	0	4	4
2002	0	2	2
2003	0	5	5
2004	1	6	7
2005	0	6	6
2006	0	1	1
2007	0	11	11
2008	3	9	12
2009	0	3	3
2010	0	6	6
2011	0	5	5
2012	0	7	7
2013	0	3	3
2014	0	2	2
2015	0	1	1
2016	1	1	2
2017	0	2	2
2018	0	6	6
2019	1	3	4
2020	0	2	2
2021	0	1	1
2022	0	1	1

Below are the most recent publications written about "Placebos" by people in Profiles.

Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, Sørrig R, Wadden TA, Wizert A, Garvey WT. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022 01 11; 327(2):138-150.

View in: PubMed
Casella JF, Barton BA, Kanter J, Black LV, Majumdar S, Inati A, Wali Y, Drachtman RA, Abboud MR, Kilinc Y, Fuh BR, Al-Khabori MK, Takemoto CM, Salman E, Sarnaik SA, Shah N, Morris CR, Keates-Baleeiro J, Raj A, Alvarez OA, Hsu LL, Thompson AA, Sisler IY, Pace BS, Noronha SA, Lasky JL, de Julian EC, Godder K, Thornburg CD, Kamberos NL, Nuss R, Marsh AM, Owen WC, Schaefer A, Tebbi CK, Chantrain CF, Cohen DE, Karakas Z, Piccone CM, George A, Fixler JM, Singleton TC, Moulton T, Quinn CT, de Castro Lobo CL, Almomen AM, Goyal-Khemka M, Maes P, Emanuele M, Gorney RT, Padgett CS, Parsley E, Kronsberg SS, Kato GJ, Gladwin MT. Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial. JAMA. 2021 04 20; 325(15):1513-1523.

View in: PubMed
Januszewski AS, Watson CJ, O'Neill V, McDonald K, Ledwidge M, Robson T, Jenkins AJ, Keech AC, McClements L. FKBPL is associated with metabolic parameters and is a novel determinant of cardiovascular disease. Sci Rep. 2020 12 10; 10(1):21655.

View in: PubMed
Deutz NE, Ziegler TR, Matheson EM, Matarese LE, Tappenden KA, Baggs GE, Nelson JL, Luo M, Hegazi R, Jonnalagadda SS. Reduced mortality risk in malnourished hospitalized older adult patients with COPD treated with a specialized oral nutritional supplement: Sub-group analysis of the NOURISH study. Clin Nutr. 2021 03; 40(3):1388-1395.

View in: PubMed
Hill KD, Baldwin HS, Bichel DP, Butts RJ, Chamberlain RC, Ellis AM, Graham EM, Hickerson J, Hornik CP, Jacobs JP, Jacobs ML, Jaquiss RD, Kannankeril PJ, O'Brien SM, Torok R, Turek JW, Li JS. Rationale and design of the STeroids to REduce Systemic inflammation after infant heart Surgery (STRESS) trial. Am Heart J. 2020 02; 220:192-202.

View in: PubMed
Kawut SM, Ellenberg SS, Krowka MJ, Goldberg D, Vargas H, Koch D, Sharkoski T, Al-Naamani N, Fox A, Brown R, Levitsky J, Oh JK, Lin G, Song N, Mottram C, Doyle MF, Kaplan DE, Gupta S, Fallon MB. Sorafenib in Hepatopulmonary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Liver Transpl. 2019 08; 25(8):1155-1164.

View in: PubMed
Wuyts W, Antin-Ozerkis D, Huggins JT, LaCamera PP, Spagnolo P, Vašáková M, Wijsenbeek MS, Polman B, Kirchgaessler KU, Scholand MB. Serious adverse events in patients with idiopathic pulmonary fibrosis in the placebo arms of 6 clinical trials. Respir Med. 2019 04; 150:120-125.

View in: PubMed
Sherman BJ, Caruso MA, McRae-Clark AL. Exogenous progesterone for cannabis withdrawal in women: Feasibility trial of a novel multimodal methodology. Pharmacol Biochem Behav. 2019 04; 179:22-26.

View in: PubMed
Fridriksson J, Rorden C, Elm J, Sen S, George MS, Bonilha L. Transcranial Direct Current Stimulation vs Sham Stimulation to Treat Aphasia After Stroke: A Randomized Clinical Trial. JAMA Neurol. 2018 12 01; 75(12):1470-1476.

View in: PubMed
Brown KK, Flaherty KR, Cottin V, Raghu G, Inoue Y, Azuma A, Huggins JT, Richeldi L, Stowasser S, Stansen W, Schlenker-Herceg R, Maher TM, Wells AU. Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis. Respir Med. 2019 01; 146:42-48.

View in: PubMed

People

Explore

Similar Concepts

Top Journals